Quipment and personnel, and is just not readily out there at many centers. Despite the fact that newer point of care methodologies have shown clinical promise with regard to quantification of platelet inhibition, agreement amongst these assays to determine sufferers with enough platelet inhibition is low.24 While the senior author has adopted the VerifyNow assay according to its superior capability to quantify the biological activity of clopidogrel more than other assays,25 we acknowledge that the lack of clear criteria for establishing platelet inhibition and the wide range of accessible tests are a limitation to our study. Finally, it deserves additional mention that these sufferers who were treated with aspirin/prasugrel DAPT have been found preprocedurally to be clopidogrel nonresponders. As such, this represents a source of choice bias for our study. In conclusion, our benefits recommend that in clopidogrel nonresponders, DAPTwith aspirin/prasugrel may possibly increase the threat of hemorrhage throughout neurointerventional surgery compared with DAPT with aspirin/clopidogrel. We recommend caution and meticulous microcatheter techniques when utilizing antiplatelet regimens involving this agent. Clearly, additional randomized investigations might be essential to figure out the clinical effects ofJ NeuroIntervent Surg 2013;5:33743. doi:ten.1136/neurintsurg2012Clinical neurologyclopidogrel resistance in the neurointerventional patient population and to validate the want for platelet inhibition laboratory testing in this subgroup. We look forward with enthusiasm to further investigation efforts within this location and to increased communication among neurointerventional surgeons about their experiences with these antiplatelet agents.Contributors Conception and design: MRR and CJM; evaluation and interpretation from the information: MRR, SHA and CJM; drafting the short article: MRR, SHA and CJM; critically revising the write-up: all authors; reviewed final version in the manuscript and authorized it for submission: all authors; administrative/technical/material assistance: MRR, SHA and CJM. Competing interests None. Ethics approval Ethics approval was provided by Washington University Medical School Human Investigation Protection Workplace. Provenance and peer assessment Not commissioned; externally peer reviewed. Data sharing statement A synopsis of our original dataset is presented inside the existing paper.912331-75-0 Order Having said that, additional data, such as explanatory material, comprehensive data sets, and so forth, is available to fellow researchers on request.1394041-21-4 site 7. Qureshi AI, Luft AR, Sharma M, et al. Prevention and remedy of thromboembolic and ischemic complications linked with endovascular procedures: aspect Idpathophysiological and pharmacological attributes. Neurosurgery 2000;46:1344e59. Gurbel PA, Bliden KP, Hiatt BL, et al.PMID:32926338 Clopidogrel for coronary stenting. Circulation 2003;107:2908e13. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel amongst 544 people. J Am Coll Cardiol 2005;45:246e51. Buonamici P, Marcucci R, Migliorini A, et al. Influence of platelet reactivity after clopidogrel administration on drugeluting stent thrombosis. J Am Coll Cardiol 2007;49:2312e17. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact in the degree of periinterventional platelet inhibition just after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742e50. Niitsu Y, Jakubowski JA, Sugidachi A, et al. Pharmacology of CS747 (prasugrel, LY640315), a novel, potent antiplat.